Charles River Laboratories International Inc
CRL: XNYS (USA)
| Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
|---|---|---|---|
| LOCK|Z@ | LOCK|&?% | LOCK|xq>smhM |
Charles River Earnings: Recovery Progress Continues Amid Strong Demand, but Expectations Look High
Charles River reported third-quarter revenue of $983 million, down 2% year over year due to divestitures, though organic revenue grew 4.7%. Management also raised its 2026 revenue outlook, now guiding to a 1.75% decline at the midpoint versus prior guidance of a 3.0% decline.
